Abstract Number: 0648 • ACR Convergence 2025
Real World Comparative Use of Anifrolumab in Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A Multicenter Cohort Study
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiorgan organ damage, and early mortality. Anifrolumab (ANI), a human monoclonal antibody targeting the…Abstract Number: 0495 • ACR Convergence 2025
Effectiveness and Safety of Iguratimod with Background Methotrexate Therapy in Indian Patients with Rheumatoid Arthritis: A Randomized Double Blinded Placebo Controlled Study
Background/Purpose: Iguratimod (IGU), an oral synthetic disease-modifying antirheumatic drug (DMARD), has shown significant efficacy and safety in rheumatoid arthritis (RA) when combined with methotrexate (MTX)…Abstract Number: 0409 • ACR Convergence 2025
Discordance Between Disease Activity and Patient-Reported Outcomes in Patients with Juvenile Idiopathic Arthritis
Background/Purpose: Outcome assessment is essential to optimize care for patients with juvenile idiopathic arthritis (JIA). Although disease activity and patient-reported outcomes (PROs) are different measures,…Abstract Number: 1509 • ACR Convergence 2025
Outcome of Newly Diagnosed SLE with Serositis and Its Clinical Features in Daily Clinical Practice: A Single Center Study
Background/Purpose: Past reports have shown that serositis is a risk factor for organ damage in patients with SLE. However, the distinct clinical features of newly…Abstract Number: 2703 • ACR Convergence 2025
Longitudinal Changes on Cranial Magnetic Resonance Imaging in Relapsing Giant Cell Arteritis
Background/Purpose: There is a need for better tools to monitor disease activity in giant cell arteritis (GCA). Prior studies demonstrated that vascular enhancement on cranial…Abstract Number: 2404 • ACR Convergence 2025
Clinical features of Elderly-onset Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystemic chronic disease characterized by a wide range of clinical and serological manifestations. It most commonly affects young…Abstract Number: 2246 • ACR Convergence 2025
Different Populations, Different SDAI Cut-Off? A Proposal for a New Remission Threshold in Brazilian RA Patients from a National Multicenter Study
Background/Purpose: Remission criteria in Rheumatoid Arthritis (RA) have continuously evolved to balance the risks of both overtreatment and undertreatment. The most recent update includes the…Abstract Number: 1661 • ACR Convergence 2025
Artificial Intelligence applied to Patient Reported Outcomes and Passive Physiologic Sensor Data can Accurately Classify Low Disease Activity in Rheumatoid Arthritis Patients
Background/Purpose: Remote therapeutic monitoring (RTM) and remote physiologic monitoring (RPM) programs have the potential to capture data between clinical visits and provide information back to…Abstract Number: 1430 • ACR Convergence 2025
Redefining BASDAI cut-offs: implications for patients’ eligibility for initiating biologic disease-modifying antirheumatic treatment in axial spondyloarthritis
Background/Purpose: In patients with axial spondyloarthritis (axSpA), high disease activity is a key indication for biological disease-modifying antirheumatic drug (bDMARD) initiation. The Axial Spondyloarthritis Disease…Abstract Number: 1310 • ACR Convergence 2025
Naturalized Language Processing Based Extraction of Rheumatoid Arthritis Disease Activity Measures from the Electronic Health Record
Background/Purpose: A treat-to-target approach in rheumatoid arthritis (RA) requires intense monitoring of RA disease activity with measures such as the clinical disease activity index (CDAI).…Abstract Number: 0620 • ACR Convergence 2025
The usefulness of neutrophil-to-lymphocyte ratio as a biomarker to predict lupus flares in patients under remission
Background/Purpose: Remission in Systemic Lupus Erythematosus (SLE) is described by the Definition of Remission in SLE (DORIS), but it is hardly achieved in clinical practice,…Abstract Number: 0493 • ACR Convergence 2025
Phase I Trial in Participants with Rheumatoid Arthritis and Healthy Volunteers with CIT-013, a First in Class NETosis Inhibitor
Background/Purpose: Aberrant Neutrophil Extracellular Trap (NET) production contributes to the pathophysiology of multiple inflammatory and autoimmune diseases including rheumatoid arthritis (RA). We report data of…Abstract Number: 0391 • ACR Convergence 2025
Which score fits best? Correlation of clinical indices of Disease Activity and Ultrasound findings in Juvenile Idiopathic Arthritis during Transitional Care
Background/Purpose: Monitoring disease activity is a crucial aspect of the treat to target paradigm in the management of rheumatic diseases. There are no standardized protocols…Abstract Number: 2686 • ACR Convergence 2025
Impact of autoimmunity, disease activity and treatment on the time course of bone density, microstructure and biomechanics in inflammatory arthritis.
Background/Purpose: RA and PsA follow different pathomechanisms and incur disease-specific erosive and osteoproliferative bone changes. We used data from a large cohort of RA and…Abstract Number: 2366 • ACR Convergence 2025
Association Between Skin and Joint Symptom Control and Patient-Reported Pain and Health Status Among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory condition primarily affecting the joints and skin.1 More severe symptoms are associated with lower health-related quality of…
ACR Meeting Abstracts